# The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

> **NCT03511703** · PHASE2 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Chemotherapy drugs+Iodized oil

## Key facts

- **NCT ID:** NCT03511703
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2018-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03511703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03511703, "The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT03511703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*